52 Weeks Enter. (531925)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a deep discount to book value: P/B of 0.31 against book value of ₹5.38 per share.
• Market cap is tiny at ₹6 Cr, so a successful asset realisation could create outsized upside.
• Price near the upper end of the 52-week range (₹1.06–₹1.69) suggests some market interest in the asset angle.
• Implied asset coverage appears substantial if the stated book value is reliable.

Concerns

• Latest quarter shows zero sales and zero profit; the operating business is effectively dormant.
• Negative ROE of -0.83% and ROCE of -0.61% indicate capital is not earning a return.
• Piotroski F-Score of 2/9 points to weak financial health and possible distress.
• No dividend, no growth data, and promoter holding not disclosed leave major transparency gaps.

AI Analysis

At first glance, 52 Weeks Enter. looks like a classic net-net or asset situation. The market capitalisation is just ₹6 crore while the book value per share stands at ₹5.38, so at ₹1.66 I am paying only 31 paisas per rupee of stated book. But Graham insisted that a bargain must also have a path to value. Here the operating engine is dead: latest quarter sales are nil and net profit is nil, the full picture shows zero growth in sales and profit, and return on equity is minus 0.83%. A company that cannot produce revenue is not a going concern; it is a shell with assets. The Piotroski F-Score of 2/9 reinforces my caution — this is not a healthy balance sheet. With debt-to-equity not disclosed and promoter holding unavailable, I cannot see who controls the company or how much risk sits above that book value. Dividend yield is zero, so I am not being paid to wait. The price has moved from ₹1.06 to ₹1.69, and at ₹1.66 we are near the high, meaning the market has already noticed the asset angle. But value investing means buying with a margin of safety. A 0.31 price-to-book ratio is interesting only if the assets are real and easily turned into cash; with no sales and negative returns, I cannot estimate a timeline. I would not classify this as a stalwart or turnaround yet. For me, this is an asset play at best — a small, speculative option on someone realising the book value. I will wait for proof of operations or a clear catalyst before committing.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer